Blauvelt CA, Zeme M, Natarajan A, Epstein A, Roh ME, Morales A, Bourdoud N, Flaherman VJ, Prahl MK, Gaw SL. JAMA Netw Open. 2025 Feb 3;8(2):e2460735. doi: 10.1001/jamanetworkopen.2024.60735.
Key Points
- Question What was the uptake of the bivalent respiratory syncytial virus (RSV) prefusion F protein–based (RSVpreF) vaccine during pregnancy and of infant monoclonal antibody against RSV (nirsevimab) during the introductory season?
- Findings In this cohort study of 647 pregnant individuals, 64.0% of eligible pregnant individuals received the RSVpreF vaccine and 70.1% of eligible neonates received nirsevimab, which translated to more than 80% coverage against RSV during all but the first month of the study period. There was no significant association between RSVpreF vaccination and preterm birth in a nested case-control study.
- Meaning This study suggests that an RSV prevention strategy that included both prenatal vaccination and infant monoclonal antibody administration had high uptake and reassuring perinatal outcomes.
Abstract
Importance Two interventions to prevent severe respiratory syncytial virus (RSV) in infants were approved in 2023—a bivalent prenatal RSV prefusion F protein–based (RSVpreF) vaccine and an infant monoclonal antibody (nirsevimab).